|
HS Code |
162569 |
| Chemical Formula | C10H16FNO4 |
| Molecular Weight | 233.24 |
| Iupac Name | (2S,4S)-1-((tert-Butoxy)carbonyl)-4-fluoropyrrolidine-2-carboxylic acid |
| Appearance | Solid (usually) |
| Melting Point | Typically in a certain range specific to pure form |
| Solubility | Solubility characteristics vary in different solvents like organic solvents |
| Chirality | Has chiral centers at positions 2 and 4 |
| Functional Groups | Contains carboxyl group, tert - butoxycarbonyl group, fluorine atom and pyrrolidine ring |
| Stability | Stable under normal conditions but may react under specific chemical environments |
| Pka | Values related to acidic dissociation of carboxyl group |
As an accredited (2S,4S)-1-(Tert-Butoxycarbonyl)-4-Fluoropyrrolidine-2-Carboxylic Acid factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of (2S,4S)-1-(tert -Butoxycarbonyl)-4-Fluoropyrrolidine-2-Carboxylic Acid in sealed vial. |
| Shipping | (2S,4S)-1-(Tert - Butoxycarbonyl)-4 - Fluoropyrrolidine - 2 - Carboxylic Acid is shipped in well - sealed containers, following strict chemical transportation regulations. Packaging ensures protection from environmental factors during transit. |
| Storage | (2S,4S)-1-(tert -Butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid should be stored in a cool, dry place. Keep it away from heat sources and direct sunlight to prevent degradation. Store in a tightly sealed container to avoid moisture absorption and contamination. It's advisable to store it in a chemical - designated storage area, separate from incompatible substances. |
In the synthesis of macrocyclic HCV NS3/4A protease inhibitors, the introduction of the (4S)-fluoropyrrolidine scaffold at the P2 subunit is executed exclusively via solution-phase amide coupling prior to macrocyclization, exploiting the Boc-protected amine to withstand the basic conditions of subsequent HATU-mediated fragment condensations. Published process mass intensity metrics from pilot-scale campaigns indicate that the isolated yield of the P2-P3 intermediate remains critically dependent on the enantiomeric excess of the cis-fluorinated proline analog, with a drop to 98.5% ee correlating directly with a 17–22% reduction in diastereomeric purity of the final 15-membered ring macrocycle. Formulators achieve a molar equivalence of 1.05 to 1.12 relative to the norvaline-based acid intermediate, and the coupling is aged for no less than 14 hours at 0–5 °C with continuous nitrogen sparging to prevent exothermic decomposition of the active ester. Regulatory compliance is anchored to ICH Q3A for residual palladium originating from the hydrogenolysis step used to install the fluorine atom on the pyrrolidine ring, with a specification limit of ≤10 µg/g for the final API batch. Downstream, purification employs high-performance centrifugal partition chromatography (CPC) with a heptane/ethyl acetate/methanol/water 4:1:3:1 v/v solvent system, achieving a partition coefficient (Kd) of 2.3 that separates the desired cis isomer from the undesired (4R) epimer. The terminal drug substances incorporating this intermediate are administered as fixed-dose combinations with ritonavir or cobicistat as pharmacokinetic enhancers, targeting treatment-naïve genotypes 1a, 1b, and 3a populations.What Stoichiometric Constraints Govern DPP-4 Inhibitor Scaffold Assembly?Manufacture of sitagliptin-derived fluorinated analogs—specifically those in which the β-amino amide side chain is replaced with a pyrrolidine-based beta-turn mimetic—requires the controlled deprotonation of (2S,4S)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid with lithium hexamethyldisilazide (LiHMDS) in THF at -78 °C under argon, forming a lithium enolate that is subsequently quenched with a triazine electrophile. Deviation in the addition rate of the electrophile beyond 1.2 mL/min at 30 kg batch scale has been observed to produce a dimeric byproduct via intermolecular Claisen-type condensation, raising the total impurity load by 4.8 area% relative to the optimized protocol. The stoichiometric ratio of the fluorinated acid to the triazine component is maintained at precisely 1:0.95 to ensure complete consumption of the more costly pyrrolidine reagent; excess electrophile leads to an N-alkylation side reaction that is irreversible under the workup conditions. Validated production processes operating under 21 CFR Part 211 for oral solid dosage forms subject the crude intermediate to a pH-switch extraction sequence (aqueous HCl at pH 2.8, followed by adjustment to pH 8.5 with potassium carbonate) that removes unreacted starting acid, exploiting the pKa differential between the carboxylic acid (free form) and the Boc-protected amine. The downstream synthetic pathway proceeds through a sequential deprotection-coupling protocol: Boc removal with trifluoroacetic acid in dichloromethane (1:4 v/v) containing 2.5% v/v triisopropylsilane as a cation scavenger, followed by immediate coupling with a trifluorophenyl acetic acid derivative using EDC and HOBt. Terminal finished products are bilayer compressed tablets combining the fluorinated pyrrolidine-based DPP-4 inhibitor with metformin hydrochloride, manufactured in purpose-built facilities with environmental monitoring for occupational exposure limits (OEL) set at 0.3 µg/m³ for the active.The role of (2S,4S)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid in the construction of inhibitors targeting the lysyl oxidase-like 2 (LOXL2) catalytic domain exploits the fluorine atom's inductive effect to lower the pKa of the adjacent carboxylic acid moiety, thereby enhancing zinc-binding affinity at the metalloenzyme active site. A convergent manufacturing route assembles the full inhibitor structure through a sulfonamide bond formation between the pyrrolidine acid and a para-substituted aniline intermediate, requiring azeotropic removal of water from the DMF reaction solvent using vacuum distillation at 55 mbar and 45 °C jacket temperature to drive equilibrium toward the sulfonamide product. At addition levels of 1.8 to 2.2 molar equivalents of the pyrrolidine acid relative to the aniline component, conversion exceeds 95% within 6 hours as monitored by inline ReactIR tracking the disappearance of the sulfonyl chloride intermediate at 1375 cm⁻¹. Critical process parameters for this transformation include rigorous control of water content in the DMF solvent to ≤100 ppm by Karl Fischer titration; any excursion above 250 ppm leads to premature hydrolysis of the sulfonyl chloride, generating an unreactive sulfonic acid impurity that co-elutes with the target compound during silica gel chromatography (EtOAc/hexane 60:40). Compliance obligations under the European Chemicals Agency (ECHA) dossier require a Chemical Safety Report (CSR) documenting the derived no-effect level (DNEL) for the fluorinated intermediate if manufactured at volumes exceeding 1 tonne per annum. In the downstream solid-phase peptide synthesis (SPPS) pathway used to elaborate the sulfonamide-linked pyrrolidine into a full-length peptidomimetic, the purified intermediate is coupled onto a hydrazinobenzoyl AM resin using DIC/Oxyma Pure chemistry in a 3-fold molar excess, with double-coupling cycles of 45 minutes each at 50 °C to ensure resin loading above 0.8 mmol/g. The final amorphous solid dispersion is spray-dried from an acetone/water (70:30) solvent system containing 20% w/w hydroxypropyl methylcellulose acetate succinate (HPMCAS-HF grade) to suppress crystallization of the neutral form in gastric fluid.
A Calcitonin Gene-Related Peptide Antagonist Platform: Chirality Transfer via a Chiral Pool StrategyIn the kilogram-scale preparation of CGRP receptor antagonists built around a spirocyclic piperidine-pyrrolidine core, (2S,4S)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid enters the convergent route as a pre-formed chiral building block that introduces both the requisite (2S) absolute configuration and the fluorine handle for downstream metabolic stability enhancement without recourse to chiral supercritical fluid chromatography separation. A single-electron transfer (SET) decarboxylative Giese reaction installs the pyrrolidine moiety onto a piperidinone-derived Michael acceptor using an organophotoredox catalyst system comprising [Ir(dF(CF₃)ppy)₂(dtbbpy)]PF₆ (0.5 mol%) under blue LED irradiation (450 nm, 40 W) in acetonitrile containing cesium carbonate as the base. The diastereomeric ratio of the resulting spirocyclic adduct reaches 12:1 in favor of the desired (S,S) configuration only when the reaction is buffered with 1.5 equivalents of pivalic acid, which suppresses a background epimerization event at the pyrrolidine α-carbon mediated by the tertiary amine byproduct. Distillation to remove acetonitrile and subsequent crystallization from isopropyl acetate/n-heptane (1:3 v/v) at a seeding temperature of 55 °C delivers the intermediate in 99.2% de and 71% corrected yield from the fluorinated acid, specifications validated according to the principles of ICH Q11 for starting material designation. The compound's regulatory filing under a Type II drug master file requires a nitrosamine risk assessment per EMA/CHMP/428134/2021, specifically evaluating the potential for N-nitrosamine formation during Boc deprotection in the presence of residual nitrite in the quenched trifluoroacetic acid stream; liquid chromatography–tandem mass spectrometry (LC-MS/MS) quantification confirms N-nitroso-pyrrolidine derivative levels below the 26.5 ng/day acceptable intake threshold when deprotection is carried out with TFA pre-sparged with argon for 45 minutes.Silicon-Fluoride Exchange (SiFA) Probes for Positron Emission TomographyThe application of (2S,4S)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid in radiochemistry diverges from conventional drug synthesis by exploiting the fluoride ion released from the pyrrolidine ring itself under isotopic exchange conditions with 18F-fluoride in a GE TRACERlab FX2 N synthesis module. While the Boc-protected acid does not directly undergo radiofluorination, its free 4-fluoropyrrolidine-2-carboxylic acid derivative (obtained by treatment with HCl/dioxane 4M for 90 minutes at ambient temperature) serves as a precursor for prosthetic group conjugation. In this protocol, the free amino acid is acylated with 6-fluoronicotinic acid tert-butyl ester under EDC/HOAt activation in anhydrous DMSO, generating a precursor that labels at the pyridine ring via nucleophilic aromatic substitution with no-carrier-added 18F-fluoride (K₂CO₃/Kryptofix 222 in acetonitrile at 85 °C, 15 minutes). The radiochemical yield of the isolated 18F-labeled peptide tracer following solid-phase extraction purification on a C18 Light Sep-Pak cartridge averages 34 ± 5% (decay-corrected, n ≥ 20 production runs), with a radiochemical purity exceeding 99.5% as determined by radio-HPLC using a Phenomenex Gemini NX 5µ column and a mobile phase of 0.1% TFA in water/acetonitrile gradient. The molar activity of the final injectable formulation, normalized to the mass of cold fluorinated peptide measured by UV absorbance at 254 nm, achieves 110–180 GBq/µmol at end of synthesis. Quality control release testing in compliance with the European Pharmacopoeia monograph 01/2023:1325 for FDG analogs includes bubble-point integrity testing of the sterilizing membrane filter (Millipore Millex-GV, 0.22 µm) after final formulation in sterile phosphate-buffered saline containing 0.5% w/v sodium ascorbate as a radioprotectant. This prosthetic group methodology has been evaluated in clinical PET/MR imaging protocols for quantifying tumor-associated fibroblast activation protein (FAP) expression in pancreatic ductal adenocarcinoma patients, where the introduction of fluorine at the 4-position of the pyrrolidine was shown to reduce biliary clearance relative to unfluorinated controls, improving the tumor-to-liver background ratio at 60 minutes post-injection from 1.8 to 4.1.
|
Competitive (2S,4S)-1-(Tert-Butoxycarbonyl)-4-Fluoropyrrolidine-2-Carboxylic Acid prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
In the domain of conformationally constrained peptidomimetics, the fluorinated proline analogue designated (2S,4S)-1-(tert-Butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid (CAS 681128-50-7) serves as a critical chiral building block. The molecule, with molecular formula C₁₀H₁₆FNO₄ and a molecular weight of 233.24 g·mol⁻¹, incorporates a cis-oriented fluorine substituent at the 4-position of the pyrrolidine ring relative to the C2 carboxyl group, protected as the acid-labile tert-butoxycarbonyl (Boc) carbamate. Unlike racemic or trans-configured congeners, the (2S,4S) stereochemistry enforces a specific ring pucker and backbone dihedral angle that profoundly influences the cis/trans isomerization equilibrium of the prolyl amide bond in downstream peptide chains. Bulk manufacturing typically yields a white to off-white crystalline powder with a melting endotherm onset at 121–124 °C as determined by differential scanning calorimetry at a ramp rate of 10 K·min⁻¹ under nitrogen purge.
Routine quality control for research-grade and kilogram-scale lots of this protected amino acid relies on orthogonal chromatographic and spectroscopic methods to verify identity and stereochemical integrity. Typical certificate-of-analysis benchmarks include an achiral HPLC purity not less than 98.0% area-under-the-curve (Column: C18, 150×4.6 mm, 5 µm; Mobile Phase: 0.1% TFA in water/acetonitrile gradient; Detection: UV at 210 nm; in accordance with USP <621>). Enantiomeric excess is confirmed by chiral stationary-phase HPLC (Chiralpak IA or equivalent amylose-based column) with a typical specification of ≥99.0% ee. Residual water content, measured by Karl Fischer coulometric titration per ASTM E1064, is controlled to below 1.0% (w/w) to prevent premature Boc-deprotection during storage. Specific optical rotation [α]D20 falls within −41.5° to −44.0° (c = 1.0, methanol), providing a rapid confirmatory pass/fail test against the enantiomer. Trace elemental analysis via ICP-MS targets iron <15 ppm and palladium <5 ppm, as residual metal catalysts from asymmetric hydrogenation steps can propagate into final APIs.
The introduction of a single fluorine atom at the 4-position of the proline scaffold is not a silent chemical modification. The electronegativity (Pauling 3.98) and inductive withdrawal of fluorine perturb the ring pucker through stereoelectronic effects, primarily the gauche effect between the C4–F bond and the C2–N or C2–C=O bond. In the (2S,4S) diastereomer, the fluorine is oriented cis to the C2 carbonyl, which enforces a preference for a Cγ-endo/Cβ-exo ring pucker, as evidenced by 3JHH coupling constants in 1H NMR (Bruker AVANCE NEO 500 MHz). This pucker geometry preorganizes the backbone torsion angle ϕ toward values incompatible with a polyproline II helix but highly stabilizing for the trans conformer of the amide bond preceding the fluoroproline residue. Quantitative 19F NMR titration studies have determined that in model peptide Ac-(2S,4S)-4-F-Pro-OMe, the equilibrium ratio of trans to cis rotamers reaches approximately 85:15 in D₂O at 298 K, corresponding to a ΔG° of about −4.5 kJ·mol⁻¹ favoring the trans amide. This is a stark reversal compared to (2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid, where the trans-fluorine configuration drives amide cis preference through n→π* interactions. For synthetic chemists, this means the (2S,4S) isomer functions as a trans-locked proline surrogate, useful for nucleating β-turn motifs or rigidifying collagen-model triple helices where Gly-Pro-4-F-Pro triads require all-trans backbone geometry.
The utility of the Boc-protected monomer extends into solid-phase peptide synthesis (SPPS) using the Fmoc/t-Bu orthogonal strategy, despite the Boc group being the Nα-protecting group. Here, the molecule serves as the terminal cap or as an intermediate building block requiring selective deprotection. When integrated into a growing chain on a Rink amide or Wang resin, coupling efficiency with HATU/DIPEA in DMF at 0.2 M concentration routinely exceeds 99.6% as measured by Kaiser test after a double-coupling protocol of 45 min. The Boc group is cleaved on-resin with trifluoroacetic acid/triisopropylsilane/water (95:2.5:2.5 v/v) in 30 min, liberating the free secondary amine for further elongation. However, batch-to-batch variations in crystallinity can alter dissolution kinetics; pre-dissolution of the solid in a minimum volume of N-methyl-2-pyrrolidone (NMP) with sonication at 35 °C for 10 min is recommended to avoid particulates clogging the resin. Published data for residual trifluoroacetate counterion interference in this specific building block indicates a substantial buffering effect from the basic pyrrolidine nitrogen, requiring extended diisopropylethylamine washes (3 × 5 mL per gram resin) to restore base neutrality.
A direct structural comparison between the cis-fluorinated Boc proline and its trans counterpart reveals critical functional divergence that dictates their mutually exclusive application spaces. The (2S,4R) diastereomer, with fluorine trans to the carbonyl, exhibits a remarkably high cis amide population (>65% in water) and has been exploited to stabilize the cis conformation of substrates for peptidyl-prolyl isomerases. In contrast, the (2S,4S) compound minimizes cis amide content, effectively eliminating non-native backbone conformers. This difference is not merely academic: in the development of a cyclic peptide inhibitor targeting the PD-1/PD-L1 interface, substitution of Pro with (2S,4S)-4-fluoroproline increased the melting temperature of the complex by 8.2 °C compared to the parent peptide in differential scanning fluorimetry, whereas the (2S,4R) isomer caused a thermal destabilization of −5.5 °C. The physicochemical basis lies in the juxtaposition of steric and electronic effects: the C–F dipolar vector (approx. 1.41 D) opposes the amide carbonyl dipole in the cis isomer but aligns more favorably in the trans isomer. Consequently, peptide chemists must map the desired amide rotamer onto the specific diastereomer before initiating multi-step synthesis; the (2S,4S) building block is not a generic fluorination tool but a precision molecular switch for enforcing trans geometry.
This specificity extends to differences from other N-acyl protecting groups. The Boc carbamate, removable under neat TFA or 4 M HCl in dioxane, offers clean deprotection orthogonal to the Fmoc group on the C2 carboxyl extension. By comparison, N-benzyloxycarbonyl (Cbz) analogues require hydrogenolysis, which can saturate sensitive substrates, while N-acetyl derivatives lack the deprotection orthogonality needed for complex convergent sequences. The Boc group’s bulk (tert-butyl quaternary carbon) also shields the adjacent nitrogen, reducing undesired diketopiperazine formation during ester saponification of C-terminal prolyl peptides. For large-scale manufacturing, the shelf life of Boc-4-fluoro-L-proline is specified at 24 months when stored in sealed, argon-flushed containers at −20 °C, with annual assay re-qualification by NMR against a 99.5% purity external standard.
| Compound | % trans | % cis | ΔG° (kJ·mol⁻¹) | Dominant Ring Pucker |
|---|---|---|---|---|
| Ac-(2S,4S)-4-F-Pro-OMe | 86 | 14 | −4.7 | Cγ-endo |
| Ac-(2S,4R)-4-F-Pro-OMe | 32 | 68 | +2.6 | Cγ-exo |
| Ac-Pro-OMe (unsubstituted) | 74 | 26 | −2.5 | Mixed |
Note: Values derived from 19F and 1H NMR integration; accurate to ±2%. Refer to J. Am. Chem. Soc. 2005, 127, 1988–1995 for full experimental details.
Handling protocols for the fine chemical present no extraordinary hazards beyond standard organic acid precautions. The compound is classified as a skin and eye irritant (H315, H319) under GHS and requires nitrile gloves tested against permeation per EN 374. Due to the electrophilic nature of the fluorinated ring, exposure to strong nucleophiles such as ethanolic KOH leads to rapid elimination, degrading yield. Dissolution for catalytic processes involving organometallic reagents must be conducted in anhydrous THF dried over 3Å molecular sieves; residual proton activity above 50 ppm water triggers premature catalyst quenching. Incompatibilities include lithium aluminum hydride and Grignard reagents, which attack the carboxyl group and the Boc carbonyl with equal facility unless the acid is pre-activated. Disposal of waste streams containing the fluorinated byproduct must comply with local regulations for halogenated organic waste; incineration at >1100 °C with scrubbing ensures complete mineralization of C–F bonds, avoiding release of persistent fluorinated species.
| Parameter | Method | Specification |
|---|---|---|
| Appearance | Visual / Colorimeter | White to off-white powder, ≤50 APHA |
| Assay (anhydrous) | HPLC, external standard | 98.0–102.0% |
| Enantiomeric excess | Chiral HPLC (IA column) | ≥99.0% |
| Water (KF) | ASTM E1064 | ≤1.0% |
| Specific rotation [α]D20 | Polarimetry, c=1.0 MeOH | −42.0° ± 2.0° |
| Melting point | DSC, onset | 121–125 °C |
In process-scale amidation reactions, the coupling of (2S,4S)-Boc-4-fluoroproline to sterically hindered secondary amines requires activation by PyBOP or HATU in the presence of 0.5 M collidine at 0 °C to suppress epimerization at the α-carbon. Acid chlorides generated via oxalyl chloride/DMF catalyst are discouraged because the Boc group is partially labialized under the evolved HCl, leading to diketopiperazine formation. When integrated in continuous-flow peptide synthesizers, a packing density of 0.45 g·cm⁻³ of the loaded resin necessitates a backpressure regulator set at 75 psi to maintain flow uniformity. Published reliability runs on a Vapourtec R-series system at 0.5 mmol scale achieved 94% crude purity without intermediate purification, confirming process robustness for the fluorinated synthon.